Soltis Investment Advisors’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$6.97M Buy
5,809
+891
+18% +$910K 0.39% 66
2026
Q1
$4.52M Sell
4,918
-1,408
-22% -$1.43M 0.29% 89
2025
Q4
$6.8M Buy
6,326
+1,745
+38% +$1.67M 0.45% 56
2025
Q3
$3.5M Buy
4,581
+94
+2% +$70K 0.24% 95
2025
Q2
$3.5M Sell
4,487
-1,042
-19% -$810K 0.27% 88
2025
Q1
$4.57M Buy
5,529
+1,524
+38% +$1.27M 0.41% 68
2024
Q4
$3.09M Buy
4,005
+2,749
+219% +$2.28M 0.29% 96
2024
Q3
$1.11M Buy
1,256
+121
+11% +$109K 0.11% 149
2024
Q2
$1.03M Buy
1,135
+218
+24% +$174K 0.11% 149
2024
Q1
$713K Sell
917
-147
-14% -$105K 0.08% 167
2023
Q4
$620K Sell
1,064
-278
-21% -$162K 0.07% 169
2023
Q3
$721K Buy
1,342
+279
+26% +$144K 0.09% 147
2023
Q2
$498K Buy
1,063
+78
+8% +$32.7K 0.06% 171
2023
Q1
$338K Buy
985
+13
+1% +$4.38K 0.04% 202
2022
Q4
$356K Buy
972
+81
+9% +$28.7K 0.05% 190
2022
Q3
$288K Buy
891
+149
+20% +$47.2K 0.04% 192
2022
Q2
$241K Buy
+742
New +$223K 0.04% 209

Other funds holding LLY

Soltis Investment Advisors's LLY Position: Q2 2026 in Review

Soltis Investment Advisors increased its Eli Lilly (LLY) stake by 18% in Q2 2026, buying an estimated $910K and bringing the position to 5,809 shares worth $6.97M. The position accounts for 0.39% of the portfolio, ranked #66.

Soltis Investment Advisors first reported a position in LLY in Q2 2022 and has held it in 17 quarters since. 2,247 funds tracked by Wall St. Rank hold LLY as of Q2 2026.

  • Soltis Investment Advisors held 5,809 shares of Eli Lilly worth $6.97M as of Q2 2026.
  • Soltis Investment Advisors bought 891 Eli Lilly shares in Q2 2026, an estimated $910K.
  • Eli Lilly made up 0.39% of Soltis Investment Advisors's portfolio in Q2 2026, its #66 holding.
  • Soltis Investment Advisors first reported a position in Eli Lilly in Q2 2022 and has held it in 17 quarters since.
  • 2,247 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.

Based on Soltis Investment Advisors's 13F filing for Q2 2026, filed 31 Jul 2026.